Kancera Logo

Kancera

Pharmaceutical company seeking a reverse takeover to leverage its public listing.

KAN | ST

Overview

Corporate Details

ISIN(s):
SE0015658570 (+1 more)
LEI:
5493002P3RCOFW6HI207
Country:
Sweden
Address:
Nanna Svartz väg 4, 171 65 SOLNA

Description

Novakand Pharma AB, formerly Kancera AB, is a pharmaceutical company that was focused on the development of small molecule therapeutics. Its primary research areas included cancer and inflammatory diseases. The company's pipeline featured drug candidates targeting the fractalkine system for cardiovascular and inflammatory conditions, as well as ROR inhibitors for oncology applications such as leukemia and solid tumors. Following a strategic review prompted by challenging capital market conditions, the company has initiated a process to seek a reverse takeover, aiming to leverage its public listing and cash assets for a merger with another entity.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Kancera filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kancera

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kancera via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Stayble Therapeutics AB Logo
Develops treatments for chronic pain originating from spinal disc conditions.
Sweden
STABL
STCUBE Logo
Develops immuno-oncology therapies targeting novel immune checkpoints for cancer.
South Korea
052020
StemRIM Inc. Logo
Develops regenerative medicine that uses the body's own stem cells for tissue repair.
Japan
4599
Surrozen, Inc./DE Logo
Develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
United States of America
SRZN
SyntekaBio,Inc. Logo
An AI-driven drug discovery company using supercomputing to accelerate development.
South Korea
226330
Tango Therapeutics, Inc. Logo
A clinical-stage biotech developing precision oncology medicines via synthetic lethality.
United States of America
TNGX
Taysha Gene Therapies, Inc. Logo
Clinical-stage company developing AAV-based gene therapies for severe CNS diseases.
United States of America
TSHA
Tectonic Therapeutic, Inc. Logo
Clinical-stage biotech developing biologics targeting G-Protein Coupled Receptors (GPCRs).
United States of America
TECX
Telomir Pharmaceuticals, Inc. Logo
Pre-clinical pharma company developing a small molecule for aging and chronic disease.
United States of America
TELO
Tempest Therapeutics, Inc. Logo
Clinical-stage oncology company developing small molecule and cell therapies for cancer.
United States of America
TPST

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.